Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Table 2 Primary analysis: results

B-cell density (mm²/mm²)	Rituximab Mean (95% CI)	Controls Mean (95% CI)	p
Tumor region	0.027 (0.021, 0.033)	0.044 (0.028, 0.062)	0.02
Non-neoplastic region	0.032 (0.011, 0.053)	0.036 (0.023, 0.048)	0.36
Within group difference
Tumor − non-neoplastic	− 0.005 (− 0.028, + 0.017)	0.009 (− 0.004, + 0.023)	0.11

Mean B-cell densities (95% CI). (Top) B cell density within the Tumor and Normal tissue regions. (Bottom) Comparison of within group difference
1. Density of Tumor for subjects treated with Rituximab
2. Density of adjacent normal tissue for subjects treated with Rituximab
3. Use one sample t test to get the mean and 95% CI. p value is from two sample t-test
For two sample t-test, the Welch (or Satterthwaite) approximation to the degrees of freedom is used

ISSN: 1479-5876